Logo

SpringWorks Therapeutics Receives the US FDA Approval for Ogsiveo (nirogacestat) for the Treatment of Desmoid Tumors

Share this
SpringWorks

SpringWorks Therapeutics Receives the US FDA Approval for Ogsiveo (nirogacestat) for the Treatment of Desmoid Tumors

Shots:

  • The approval was based on the P-III study (Defi) evaluating nirogacestat, vs PBO on Desmoid Tumor patients (n=142). The study met its 1EP depicted improved PFS & 71% reduction in disease progression
  • Based on RECIST v1.1 ORR was 41% vs 8%; the complete response rate was 7% vs 0%; mDoR was 5.6 vs 11.1mos. Additionally, median PFS was not met in the nirogacestat arm & was 15.1mos. in PBO arm. Furthermore, Ogsiveo showed early & persistent benefits in patient-reported outcomes (PROs) such as pain, a symptom unique to desmoid tumors, role- & physical-functioning, & overall health-related quality of life
  • The company anticipates submitting MAA for Ogsiveo, an oral, selective, small-molecule gamma-secretase inhibitor to the EMA in H1’24

Ref: SpringWorks | Image: SpringWorks

Related News:- SpringWorks Therapeutics Reports the Results for Mirdametinib in P-IIb Trial to Treat Neurofibromatosis Type 1-Associated Plexiform Neurofibromas (NF1-PN)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions